Boston skyline reflected in Charles River at golden hour

2026 agencies

Best Investor Relations Agencies in Boston

Top IR firms for Boston biotech, pharma, and healthcare companies with specialized life sciences capital markets expertise.

Boston is the biotech capital of the world, home to more than 1,000 life sciences companies and the institutional investors who fund them. Investor relations in Boston demands a unique skill set — the ability to translate complex clinical data into investment narratives, manage the binary risk of FDA decisions, and maintain institutional support through multi-year development timelines.

The best Boston IR agencies combine deep scientific literacy with capital markets sophistication. They understand the difference between Phase 2 and Phase 3 readouts, can explain mechanism of action to generalist investors, and know which biotech-focused funds are actively deploying capital.

What to Look For

Life Sciences Expertise

Deep understanding of clinical development, FDA regulatory pathways, and the ability to communicate complex scientific data to financial audiences.

Weight: Critical

Healthcare Investor Network

Established relationships with healthcare-focused institutional investors including RA Capital, OrbiMed, Perceptive, Deerfield, and sector-dedicated teams at Fidelity and Wellington.

Weight: Critical

Analyst Relations

Connections with sell-side healthcare analysts at major banks and boutique research firms who cover biotech, pharma, and medtech.

Weight: High

Clinical Data Communication

Track record of successfully communicating clinical trial results — both positive and negative — to investors and analysts.

Weight: High

IPO and Financing Experience

Experience supporting biotech IPOs, follow-on offerings, and other capital raises in the life sciences sector.

Weight: Medium

Top Providers Ranked

Stern IR

Stern Investor Relations is one of the largest dedicated IR firms in the US, with a Boston team focused on life-sciences, biotech, and healthcare issuers. Strategic counsel through IPOs, secondary offerings, and earnings cycles, with deep relationships across buy-side healthcare specialists and sell-side biotech analysts. Used by growth-stage biotechs preparing for the Street and established names managing complex investor narratives.

AMW

Featured

Marketing services and AI software from one accountable team

Custom — scoped per engagement

typical range

AMW is a marketing agency and software company operating since 1997. Campaigns — PR, content, events, and digital — are run by a dedicated team on AMW's own AI-powered suite, so strategy, execution, and reporting live in one place. Engagements are transparently scoped and deliverable-based, with placement guarantees on PR work.

Strengths

Services + software under one roof
Nearly 30 years in business (founded 1997)
Placement guarantees on PR engagements
Transparent, deliverable-based scopes

Considerations

Engagements are scoped with the AMW team — not self-serve
Best fit for businesses ready for a sustained program

Best for: Businesses that want services and the software they run on from one partner

Get a Free Quote

Argot Partners

Argot Partners runs a healthcare-focused IR and corporate-communications practice with significant Boston biotech footprint. Strongest on positioning emerging therapeutic platforms, navigating clinical-trial readouts in market-moving moments, and aligning IR with corporate-development storytelling. Frequently engaged for IPO road-show preparation and the first 12 months of public-market life.

ICR Healthcare

ICR's healthcare practice covers Boston life-sciences and medtech issuers from pre-IPO through mid-cap. Integrated IR + PR offering — same firm handles investor messaging, financial press, and crisis communications — which simplifies coordination during data readouts, M&A announcements, and earnings. Strong on conference scheduling and proactive non-deal roadshow outreach.

Burns McClellan

Burns McClellan is a smaller boutique focused exclusively on life-sciences and healthcare communications, with senior-led teams that stay on accounts through clinical cycles. Boston engagements skew biotech and medtech. Strongest fit for issuers who want a single senior IR contact who knows their pipeline cold, rather than rotating junior staff across a large book.

LifeSci Advisors

LifeSci Advisors is a life-sciences-only IR and capital-markets advisory firm with offices in Boston. Differentiated by a venture-banking-adjacent perspective — the firm advises issuers on capital-raise positioning alongside traditional IR services. Common engagement: pre-IPO through second financing, with explicit handoffs from corporate-development to public-markets IR work.

Rx Communications

Rx Communications focuses on small- and mid-cap healthcare IR with a Boston presence serving emerging biotech, medtech, and specialty pharma. Senior-heavy teams and a flat model — clients typically work with the same lead counsel across years rather than rotating account managers. Strong fit for issuers under $1B market cap who want partner-level attention without enterprise pricing.

Real Chemistry

Real Chemistry is a large healthcare communications firm with a Boston life-sciences-IR practice integrated into a broader marketing, medical-affairs, and analytics offering. Best suited for issuers who want IR coordinated with patient-advocacy, KOL, and HCP communications under one roof. Scale advantage matters for global launches and multi-market readouts; less optimal for small-cap issuers wanting boutique attention.

Want to be featured on this list?

Companies can apply for a featured listing through our directory. All applications are editorially reviewed — we only approve companies that meet our quality standards.

Featured listings are paid placements and include a company profile, logo, specialties, and a backlink to your website. Rankings remain editorially independent.

Apply for a Listing

AMW Suite · Beta

Software for running a business — sales to delivery.

CRM, proposals, client portal, marketing — every app and every AI agent in one workspace.

See the Suite

Frequently Asked Questions

How much do Boston biotech IR firms charge?

Boston biotech IR retainers range from $6,000-$15,000/month for early-stage companies to $20,000-$45,000/month for commercial-stage or large-cap pharma companies. Clinical data readout support is often billed as an additional project fee.

Do I need a life sciences specialist for biotech IR?

Strongly recommended. Biotech IR requires understanding of clinical development, FDA pathways, and the ability to communicate scientific data to financial audiences. Generalist IR firms typically lack the scientific literacy needed for credible biotech communication.

How do Boston IR firms handle clinical data readouts?

Top Boston IR firms prepare extensively for data readouts — developing messaging for both positive and negative scenarios, pre-briefing key investors and analysts, and managing the post-data communication cycle to ensure accurate interpretation of results.

When should a biotech company hire an IR firm?

Ideally 6-12 months before an IPO or a major clinical catalyst. Pre-revenue biotech companies benefit from building investor relationships early, particularly ahead of data readouts that could significantly move the stock.

How important are healthcare-focused conferences for Boston biotech IR?

Critical. Events like J.P. Morgan Healthcare Conference, ASCO, ASH, and sector-specific medical meetings are essential for biotech investor outreach. Your IR firm should secure presentation slots and arrange investor meetings at these events.

Can a Boston IR firm help with FDA advisory committee preparation?

Yes. Top life sciences IR firms have experience preparing companies for FDA advisory committee meetings, including investor communication strategy for both approval and rejection scenarios.

What makes biotech IR different from other sectors?

Biotech IR involves communicating binary event risk (clinical trial outcomes), managing long development timelines without revenue, explaining complex science to financial audiences, and navigating FDA regulatory milestones — all while maintaining investor confidence and managing cash runway expectations.

Should my biotech IR firm also handle medical affairs communication?

Some firms offer integrated IR and medical affairs communication, which ensures consistency between scientific presentations and investor messaging. However, these are distinct functions and not all IR firms have medical affairs capabilities.

Related Resources

Want a quote from AMW?

Share a few details — we'll come back with scope, timing, and price. No obligation.

Get a Free Quote View All Services

The AMW Suite